Karthik Ravi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karthik Ravi has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Abed Rahman Kawakibi
University of Michigan, Ann Arbor, Michigan
58 shared publications - Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
58 shared publications - Akash Deogharkar
University of Michigan, Ann Arbor, Michigan
58 shared publications - Alexander R. Judkins
Children's Hospital Los Angeles
58 shared publications - Alyssa Waugh
University of Michigan, Ann Arbor, Michigan
58 shared publications - Andrea Franson
Department of Pediatrics, University of Michigan Medical School, Ann Arbor, USA
58 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (18)
Supraorbital craniotomy for focal frontal epilepsy via eyebrow incision and guided by in situ stereo-EEG electrodes: illustrative case
BACKGROUND: Focal cortical dysplasia (FCD) is a common cause of focal, pediatric, drug-resistant epilepsy. For FCDs in the frontal lobe, resection may be hampered by both difficult access and proximal eloquent cortex. Stereo-EEG (sEEG) can help define the boundaries of the suspected seizure onset zone (SOZ); however, subsequent epilepsy resections often rely on lateral approaches, requiring electrode removal before resection. Nevertheless, for some lesions, especially those in the frontopolar region, skull base approaches provide an in-line, minimally invasive trajectory that allows electrodes to remain in situ during resection as both anatomical landmarks and a source of intraoperative, continuous electrocorticography (ECoG). OBSERVATIONS: A 17-year-old, otherwise healthy male presented with 2 years of epilepsy secondary to a left frontopolar FCD. Left frontal and temporal sEEG confirmed a lesion-confined SOZ. The patient underwent a left supraorbital keyhole craniotomy via eyebrow incision for resection of the identified epileptogenic focus. All sEEG electrodes remained implanted during resection, serving as anatomical and electrophysiological surgical adjuncts. LESSONS: The authors present a case of frontopolar FCD-associated epilepsy resected using a supraorbital craniotomy via eyebrow approach. We highlight the utility of leveraging previously placed sEEG electrodes for intraoperative ECoG, resulting in gross-total resection and seizure freedom a year postoperatively. https://thejns.org/doi/10.3171/CASE25428
- 3 November 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (18)
Open AccessSupraorbital craniotomy for focal frontal epilepsy via eyebrow incision and guided by in situ stereo-EEG electrodes: illustrative case
BACKGROUND: Focal cortical dysplasia (FCD) is a common cause of focal, pediatric, drug-resistant epilepsy. For FCDs in the frontal lobe, resection may be hampered by both difficult access and proximal eloquent cortex. Stereo-EEG (sEEG) can help define the boundaries of the suspected seizure onset zone (SOZ); however, subsequent epilepsy resections often rely on lateral approaches, requiring electrode removal before resection. Nevertheless, for some lesions, especially those in the frontopolar region, skull base approaches provide an in-line, minimally invasive trajectory that allows electrodes to remain in situ during resection as both anatomical landmarks and a source of intraoperative, continuous electrocorticography (ECoG). OBSERVATIONS: A 17-year-old, otherwise healthy male presented with 2 years of epilepsy secondary to a left frontopolar FCD. Left frontal and temporal sEEG confirmed a lesion-confined SOZ. The patient underwent a left supraorbital keyhole craniotomy via eyebrow incision for resection of the identified epileptogenic focus. All sEEG electrodes remained implanted during resection, serving as anatomical and electrophysiological surgical adjuncts. LESSONS: The authors present a case of frontopolar FCD-associated epilepsy resected using a supraorbital craniotomy via eyebrow approach. We highlight the utility of leveraging previously placed sEEG electrodes for intraoperative ECoG, resulting in gross-total resection and seizure freedom a year postoperatively. https://thejns.org/doi/10.3171/CASE25428
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.